The Panchkula-based company said it plans to roll out the drug by the third quarter of 2014 and is eyeing sizeable share in Australia's USD 15 million Meropenem market in the first year of launch.
Pharma major Venus Remedies Ltd today said it has received marketing authorisation for its antibiotic drug Meropenem from Australian regulator TGA and has tied up with Lupin to sell the drug there.
The Panchkula-based company said it plans to roll out the drug by the third quarter of 2014 and is eyeing sizeable share in Australia's USD 15 million Meropenem market in the first year of launch.
Also Read: Sun Pharma settles Novartis lawsuit over drug
"The marketing authorisation from TGA (Therapeutic Goods Administration) has once again proved the company's capabilities in developing world-class products that meet the most stringent regulatory requirements," said Venus Chairman and MD Pawan Chaudhary in a statement.He said the company has tied-up with Lupin to market this drug in Australia. Meropenem is an off-patent antibacterial agent of carbapenem class of antibiotics that caters to diseases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children.
Venus Remedies is already selling Meropenem in lucrative markets like Europe, New Zealand and Saudi Arabia. It is also in the process of extending sales operations to other regulated markets like Canada and Switzerland, Chaudhary said. With marketing approvals from more than 35 countries, Venus Remedies is poised to capture a significant share in the USD 1.3 billion global Meropenem market, he said.
Venus Remedies stock price
On May 19, 2014, Venus Remedies closed at Rs 314.90, up Rs 13.15, or 4.36 percent. The 52-week high of the share was Rs 350.00 and the 52-week low was Rs 140.00.
The company's trailing 12-month (TTM) EPS was at Rs 51.99 per share as per the quarter ended December 2013. The stock's price-to-earnings (P/E) ratio was 6.06. The latest book value of the company is Rs 339.42 per share. At current value, the price-to-book value of the company is 0.93.
Anda sedang membaca artikel tentang
Venus to sell Meropenem in Australia; ties up with Lupin
Dengan url
http://kebugaranhidup.blogspot.com/2014/05/venus-to-sell-meropenem-in-australia.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Venus to sell Meropenem in Australia; ties up with Lupin
namun jangan lupa untuk meletakkan link
Venus to sell Meropenem in Australia; ties up with Lupin
sebagai sumbernya
0 komentar:
Posting Komentar